CD20-CD3 Quiz

Quiz

Treating DLBCL With Odronextamab Monotherapy

12/18/2023

Updated analysis of outcomes in the ELM-1 trial demonstrated that CD20-CD3 bispecific antibody odronextamab monotherapy demonstrated _____ among heavily pretreated patients with diffuse large B-cell lymphoma (DLBCL) who had progressed after...

Updated analysis of outcomes in...

12/18/2023

Oncology

Quiz

Mosunetuzumab Monotherapy for FL and MZL With No G2+ CRS or ICANS

12/18/2023

True or False: Fixed-duration mosunetuzumab monotherapy demonstrated a high complete response rate and well-tolerated safety among patients with follicular lymphoma and MZL with no G2+ cytokine release syndrome and no ICANS of any grade.

True or False: Fixed-duration...

12/18/2023

Oncology

Quiz

Quiz: CD20-CD3 for Malignant B-Cells

03/20/2023

CD20 is a ________ protein that is expressed on the surface of normal and malignant B lymphocytes. CD3 is a ________ protein that is made up of 4 molecules (γ, δ, ϵ, and ζ).

CD20 is a ________ protein that...

03/20/2023

Oncology

Quiz

Quiz: Complete Response Rate of Mosunetuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

12/05/2022

According to a phase 2 study, what was the complete response rate of mosunetuzumab in patients with relapsed/refractory follicular lymphoma who had previously been treated with ≥2 therapies?

According to a phase 2 study,...

12/05/2022

Oncology

Quiz

Quiz: Odronextamab Monotherapy in Heavily Pretreated Patients With B-cell Non-Hodgkin Lymphoma

12/01/2022

True or False: Odronextamab monotherapy demonstrated a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent study.

True or False: Odronextamab...

12/01/2022

Oncology

Quiz

Quiz: Does This CD20xCD3 Bispecific Antibody Show High Potency?

04/11/2022

True or false: Mosunetuzumab showed high potency in patients with R/R FL.

True or false: Mosunetuzumab...

04/11/2022

Oncology

Recent News

News

Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

06/05/2026

Emily Estrada

Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

Results from a phase 1 study...

06/05/2026

Oncology

News

Fedratinib Demonstrates Potential Clinical Promise in Patients With Proliferative MDS/MPNs and Chronic Neutrophilic Leukemia

06/05/2026

Emily Estrada

Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.

Results from a phase 2 study...

06/05/2026

Oncology

News

Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma

06/05/2026

Emily Estrada

Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.

Results from a phase 2 study...

06/05/2026

Oncology

News

ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma

06/05/2026

Emily Estrada

Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.

Results from a phase 2 trial...

06/05/2026

Oncology

News

Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma

06/01/2026

Emily Estrada

Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.

Results from the...

06/01/2026

Oncology

News

Ropeginterferon Shows Efficacy Across Treatment Lines and Mutation Subtypes in Essential Thrombocythemia

06/01/2026

Stephanie Holland

Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.

Results from an integrated...

06/01/2026

Oncology

News

Asandeutertinib Demonstrates Superior Intracranial Efficacy in EGFR-Mutated NSCLC

05/31/2026

Emily Estrada

Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.

Results from the ESAONA...

05/31/2026

Oncology

News

BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer

05/31/2026

Stephanie Holland

First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...

First-line encorafenib,...

05/31/2026

Oncology

News

HARMONi-6 Trial Positions Ivonescimab Plus Chemotherapy as New First-Line Standard of Care in Squamous NSCLC

05/31/2026

Emily Estrada

Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.

Results from the HARMONi-6 trial...

05/31/2026

Oncology

News

Metronomic Chemo-Immunotherapy Improves Survival in Metastatic Head and Neck Cancer

05/31/2026

Stephanie Holland

Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.

Results from a phase 3 trial...

05/31/2026

Oncology